inverse agonists
Recently Published Documents


TOTAL DOCUMENTS

537
(FIVE YEARS 92)

H-INDEX

48
(FIVE YEARS 6)

2021 ◽  
pp. 105540
Author(s):  
Bahaa Elgendy ◽  
Kristine Griffett ◽  
Lamees Hegazy ◽  
Paolo Di Fruscia ◽  
Kirby Sample ◽  
...  

2021 ◽  
Vol 226 ◽  
pp. 113797
Author(s):  
Christian Schütz ◽  
Amir Hodzic ◽  
Mostafa Hamed ◽  
Ahmed S. Abdelsamie ◽  
Andreas M. Kany ◽  
...  

Molecules ◽  
2021 ◽  
Vol 26 (21) ◽  
pp. 6693
Author(s):  
Parthasaradhireddy Tanguturi ◽  
Vibha Pathak ◽  
Sixue Zhang ◽  
Omar Moukha-Chafiq ◽  
Corinne E. Augelli-Szafran ◽  
...  

The delta opioid receptor (DOR) is a crucial receptor system that regulates pain, mood, anxiety, and similar mental states. DOR agonists, such as SNC80, and DOR-neutral antagonists, such as naltrindole, have been developed to investigate the DOR in vivo and as potential therapeutics for pain and depression. However, few inverse agonists and non-competitive/irreversible antagonists have been developed, and none are widely available. This leaves a gap in our pharmacological toolbox and limits our ability to investigate the biology of this receptor. Thus, we designed and synthesized the novel compounds SRI-9342 as an irreversible antagonist and SRI-45127/SRI-45128 as inverse agonists. Then, these compounds were evaluated in vitro for their binding affinity by radioligand binding and functional activity by 35S-GTPγS coupling and cAMP accumulation in cells expressing the human DOR. All three compounds demonstrated high binding affinity and selectivity at the DOR, and all three displayed their hypothesized molecular pharmacology of irreversible antagonism (SRI-9342) or inverse agonism (SRI-45127/SRI-45128). Together, these results demonstrate that we have designed new inverse agonists and irreversible antagonists of the DOR based on a novel chemical scaffold. These new compounds will provide new tools to investigate the biology of the DOR or even new potential therapeutics.


2021 ◽  
Author(s):  
Ekaterina Fokina ◽  
Andrey Bakhtyukov ◽  
Kira Derkach ◽  
Viktor Sorokoumov ◽  
Lev Klys ◽  
...  

2021 ◽  
Vol 22 (19) ◽  
pp. 10638
Author(s):  
Chayma El Khamlichi ◽  
Laetitia Cobret ◽  
Jean-Michel Arrang ◽  
Séverine Morisset-Lopez

G-protein-coupled receptors (GPCRs) are dimeric proteins, but the functional consequences of the process are still debated. Active GPCR conformations are promoted either by agonists or constitutive activity. Inverse agonists decrease constitutive activity by promoting inactive conformations. The histamine H3 receptor (H3R) is the target of choice for the study of GPCRs because it displays high constitutive activity. Here, we study the dimerization of recombinant and brain H3R and explore the effects of H3R ligands of different intrinsic efficacy on dimerization. Co-immunoprecipitations and Western blots showed that H3R dimers co-exist with monomers in transfected HEK 293 cells and in rodent brains. Bioluminescence energy transfer (BRET) analysis confirmed the existence of spontaneous H3R dimers, not only in living HEK 293 cells but also in transfected cortical neurons. In both cells, agonists and constitutive activity of the H3R decreased BRET signals, whereas inverse agonists and GTPγS, which promote inactive conformations, increased BRET signals. These findings show the existence of spontaneous H3R dimers not only in heterologous systems but also in native tissues, which are able to adopt a number of allosteric conformations, from more inactive to more active states.


2021 ◽  
pp. 105218
Author(s):  
Marcin Drop ◽  
Florian Jacquot ◽  
Vittorio Canale ◽  
Severine Chaumont-Dubel ◽  
Maria Walczak ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document